{
  "question_stem": {
    "en": "A 6-year-old girl is brought to the clinic due to an itchy rash on her face. The patient's mother says the rash began approximately 3 weeks ago as dry skin on both of her cheeks. Over the past few days, it has progressed with areas of weeping and increased redness, and the patient has had to wear mittens to limit irritation from constant scratching. The patient has a history of similar rashes involving the flexural areas of her elbows and knees that resolved following treatment with topical corticosteroids. Vital signs are normal. Physical examination shows erythema of the bilateral cheeks and chin with crusting and oozing {{exhibit_1}}. The patient is prescribed a course of topical tacrolimus. Which of the following is the most likely mechanism of action of this drug?",
    "zh": "一名6岁女孩因面部瘙痒性皮疹来就诊。患者的母亲说，大约3周前，皮疹开始于双颊的皮肤干燥。在过去的几天里，病情进展，出现渗出和红肿，并且患者不得不戴上手套以限制持续抓挠引起的刺激。患者有类似的皮疹病史，涉及其肘部和膝盖的屈曲部位，在使用局部皮质类固醇治疗后缓解。生命体征正常。体格检查显示双侧脸颊和下巴红斑，伴有结痂和渗出{{exhibit_1}}。患者被开了局部他克莫司疗程。以下哪项是该药物最可能的作用机制？"
  },
  "question": {
    "en": "Which of the following is the most likely mechanism of action of this drug?",
    "zh": "以下哪项是该药物最可能的作用机制？"
  },
  "options": {
    "A": {
      "en": "Inhibition of histamine granule release",
      "zh": "抑制组胺颗粒释放"
    },
    "B": {
      "en": "Inhibition of T-lymphocyte signaling",
      "zh": "抑制 T 淋巴细胞信号传导"
    },
    "C": {
      "en": "Prevention of IgE binding to mast cells",
      "zh": "阻止 IgE 与肥大细胞结合"
    },
    "D": {
      "en": "Selective blockade of the IL-4 receptor",
      "zh": "选择性阻断 IL-4 受体"
    },
    "E": {
      "en": "Stimulation of B-lymphocyte apoptosis",
      "zh": "刺激 B 淋巴细胞凋亡"
    }
  },
  "correct_answer": "B",
  "explanation": {
    "en": "This patient most likely has atopic dermatitis (eczema), an inflammatory condition that begins in infancy or early childhood. Pathogenesis involves genetically mediated skin barrier dysfunction (eg, filaggrin mutation) and a dysregulated immune response that favors IgE production, mast cell and eosinophil activation, and overproduction of Th2 cytokines. \n\nLoss of epidermal water content, increased permeability to allergens/irritants, and inflammation result in dry skin, intense pruritus, erythema, and, sometimes, weeping and crusting (as seen in this patient). Distribution typically includes the face and the flexural areas of the elbows and knees in children.\n\nFirst-line treatment of atopic dermatitis is topical corticosteroids. However, due to concerns for corticosteroid-induced atrophy in areas with thin skin (eg, face, neck, axilla, groin), second-line therapy with calcineurin inhibitors (eg, tacrolimus, pimecrolimus) can be used instead. Through the inhibition of calcineurin, a lymphocyte-specific phosphatase, these medications inhibit T-cell signaling that would normally lead to transcription of the proinflammatory cytokine IL-2. Reduced IL-2 leads to decreased T-cell activation and proliferation, and, in turn, inflammation. {{exhibit_2}}\n\n(Choices A and C) Cromolyn is a mast cell stabilizer that inhibits histamine granule release from mast cells and can be used to treat allergic rhinitis or systemic mastocytosis. Omalizumab, a monoclonal anti-IgE antibody, prevents binding of IgE to mast cells and basophils and is most commonly used to treat persistent, severe asthma.\n\n(Choice D) IL-4 stimulates IgE production and the differentiation of naive CD4 T cells to Th2 cells, which exacerbate the inflammatory response in atopic dermatitis. Dupilumab is a human monoclonal antibody that inhibits IL-4 action by antagonizing the IL-4 receptor. It can be considered for severe atopic dermatitis refractory to topical therapies.\n\n(Choice E) Rituximab is a monoclonal antibody against the CD20 antigen on B lymphocytes. Once bound, rituximab initiates complement and cell-mediated B-cell cytotoxicity. It is used to treat hematologic malignancies (eg, chronic lymphocytic leukemia) and rheumatologic diseases (eg, rheumatoid arthritis).\n\nEducational objective:\nAtopic dermatitis is an inflammatory condition that can be treated with calcineurin inhibitors (eg, pimecrolimus, tacrolimus) as second-line therapy after topical corticosteroids. Calcineurin inhibitors work by inhibiting T-cell signaling needed to transcribe the proinflammatory cytokine IL-2, thereby decreasing inflammation. {{exhibit_3}} {{exhibit_4}}",
    "zh": "该患者最有可能患有特应性皮炎（湿疹），这是一种炎症性疾病，始于婴儿期或幼儿期。发病机制涉及基因介导的皮肤屏障功能障碍（例如，聚丝蛋白突变）和失调的免疫反应，有利于 IgE 产生、肥大细胞和嗜酸性粒细胞激活以及 Th2 细胞因子的过度产生。\n\n表皮含水量降低、对过敏原/刺激物的通透性增加和炎症会导致皮肤干燥、剧烈瘙痒、红斑，有时还会出现渗出和结痂（如该患者所示）。分布通常包括儿童的面部和肘部和膝盖的屈曲部位。\n\n特应性皮炎的一线治疗是局部皮质类固醇。然而，由于担心在皮肤较薄的区域（例如，面部、颈部、腋窝、腹股沟）发生皮质类固醇诱导的萎缩，可以使用二线治疗，使用钙调神经磷酸酶抑制剂（例如，他克莫司、吡美莫司）。通过抑制钙调神经磷酸酶（一种淋巴细胞特异性磷酸酶），这些药物抑制 T 细胞信号传导，而 T 细胞信号传导通常会导致促炎细胞因子 IL-2 的转录。IL-2 的减少导致 T 细胞活化和增殖的减少，进而导致炎症。{{exhibit_2}}\n\n（选项 A 和 C）色甘酸是一种肥大细胞稳定剂，可抑制组胺颗粒从肥大细胞释放，可用于治疗过敏性鼻炎或系统性肥大细胞增多症。奥马珠单抗是一种单克隆抗 IgE 抗体，可防止 IgE 与肥大细胞和嗜碱性粒细胞结合，最常用于治疗持续性、重度哮喘。\n\n（选项 D）IL-4 刺激 IgE 的产生和幼稚 CD4 T 细胞向 Th2 细胞的分化，从而加剧特应性皮炎的炎症反应。度普利尤单抗是一种人源单克隆抗体，通过拮抗 IL-4 受体来抑制 IL-4 的作用。对于对局部治疗无效的严重特应性皮炎，可以考虑使用它。\n\n（选项 E）利妥昔单抗是一种针对 B 淋巴细胞 CD20 抗原的单克隆抗体。一旦结合，利妥昔单抗就会启动补体和细胞介导的 B 细胞细胞毒作用。它用于治疗血液系统恶性肿瘤（例如，慢性淋巴细胞性白血病）和风湿性疾病（例如，类风湿性关节炎）。\n\n教育目标：\n特应性皮炎是一种炎症性疾病，在局部皮质类固醇治疗后，可以使用钙调神经磷酸酶抑制剂（例如，吡美莫司、他克莫司）作为二线治疗。钙调神经磷酸酶抑制剂通过抑制转录促炎细胞因子 IL-2 所需的 T 细胞信号传导来发挥作用，从而减少炎症。{{exhibit_3}} {{exhibit_4}}"
  },
  "summary": {
    "en": "This question tests knowledge of the pathophysiology of atopic dermatitis and the mechanism of action of tacrolimus, a calcineurin inhibitor used as a second-line treatment. \n\nTo solve this question, recognize the clinical presentation of atopic dermatitis and recall that tacrolimus inhibits T-cell signaling by inhibiting calcineurin, which is necessary for the transcription of proinflammatory cytokine IL-2.",
    "zh": "此问题测试对特应性皮炎的病理生理学以及他克莫司（一种用作二线治疗的钙调神经磷酸酶抑制剂）的作用机制的了解。\n\n要解决此问题，需要识别特应性皮炎的临床表现，并记住他克莫司通过抑制钙调神经磷酸酶来抑制 T 细胞信号传导，而钙调神经磷酸酶是转录促炎细胞因子 IL-2 所必需的。"
  },
  "tags": "Atopic dermatitis; Tacrolimus; Calcineurin inhibitors; T-lymphocyte signaling; IL-2; Dermatology; Immunology",
  "category": "Derma",
  "question_id": "18707",
  "has_exhibits": true,
  "exhibit_count": 4,
  "exhibit_files": [
    "image1.jpg",
    "image2.jpg",
    "image3.jpg",
    "image4.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Derma 23\\18707",
  "extracted_at": "2025-11-05T13:55:01.290945",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:34:48.888768",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}